– First regimen to be approved in India to demonstrate superiority to platinum-containing chemotherapy, the current standard of care for adult patients with unresectable or metastatic urothelial cancer for nearly 40 years — Central Drugs Standard Control Organization approval was based on the global Phase 3 EV-302 trial (also known as KEYNOTE-A39) where the combination treatment nearly doubled median overall survival and significantly extended progression free survival outcomes1 (Brand Connect Initiative)
News
PADCEVTM (enfortumab vedotin) in Combination with pembrolizumab is Now Available for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy in India
May 21, 2026– First regimen to be approved in India to demonstrate superiority to platinum-containing chemotherapy, the current standard of care for adult patients with unresectable or metastatic urothelial cancer for nearly 40 years — Central Drugs Standard Control Organization approval was based on the global Phase 3 EV-302 trial (also known as KEYNOTE-A39) where the combination treatment nearly doubled median overall survival and significantly extended progression free survival outcomes1 (Brand Connect Initiative)